Pfizer wins EU’s approval for Ibrance as Novartis readies rival drug

LONDON (Reuters) - U.S. drugmaker Pfizer said on Wednesday it had won approval from the European Union for its best-selling breast cancer drug Ibrance, making it the first medicine of its kind to reac…
Read the full story: Reuters: Health News